← 產業報告目錄
Insulin Sensitizers Market Size, Share & Trends Analysis Report Type of Insulin Sensitizers (Thiazolidinediones (TZDs), Biguanides, Incretin-based therapies, Others), By Indication (Type 2 Diabetes, Prediabetes, Polycystic Ovary Syndrome (PCOS)), By Route of Administration, By Distribution Channel, Region And Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-07頁數 180報告編號 INSIGHTACE-f75bb464d1
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2022 valuation of USD 14.27 billion, the global Insulin Sensitizers Market is forecasted to advance to USD 23.35 billion by 2031, demonstrating a CAGR of 5.8% during the 2023–2031 forecast window.
Insulin Sensitizers encompasses referred to as "insulin sensitizers" and are also euglycemics, which normalize blood sugar. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Insulin Sensitizers Market Snapshot
Chapter 4. Global Insulin Sensitizers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Insulin Sensitizers Estimates & Trend Analysis
5.1. By Type of Insulin Sensitizers, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Type of Insulin Sensitizers:
5.2.1. Thiazolidinediones (TZDs)
5.2.2. Biguanides
5.2.3. Incretin-based therapies
5.2.4. Others
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indication:
6.2.1. Type 2 Diabetes
6.2.2. Prediabetes
6.2.3. Polycystic Ovary Syndrome (PCOS)
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. By Route of Administration & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Route of Administration:
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. By Distribution Channel & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Insulin Sensitizers Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Type of Insulin Sensitizers, 2019-2031
9.1.2. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031
9.1.3. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
9.1.4. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
9.1.5. North America Insulin Sensitizers Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, 2019-2031
9.2.2. Europe Insulin Sensitizers Market revenue (US$ Million) By Indication, 2019-2031
9.2.3. Europe Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, 2019-2031
9.2.4. Europe Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, 2019-2031
9.2.5. Europe Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, 2019-2031
9.3.2. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Indication, 2019-2031
9.3.3. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, 2019-2031
9.3.4. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, 2019-2031
9.3.5. Asia Pacific Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, (US$ Million) 2019-2031
9.4.2. Latin America Insulin Sensitizers Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
9.4.3. Latin America Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031
9.4.4. Latin America Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
9.4.5. Latin America Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Type of Insulin Sensitizers, (US$ Million) 2019-2031
9.5.2. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
9.5.3. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031
9.5.4. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
9.5.5. Middle East & Africa Insulin Sensitizers Market revenue (US$ Million) by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Eli Lilly and Company
10.2.2. Novo Nordisk
10.2.3. Sanofi
10.2.4. Merck & Co.
10.2.5. Bristol Myers Squibb
10.2.6. AstraZeneca
10.2.7. Boehringer Ingelheim
10.2.8. Johnson & Johnson
10.2.9. Takeda Pharmaceutical
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們